Processa Pharmaceuticals Inc stock is traded at $1.94, with a volume of 1,791. It is up +5.43% in the last 24 hours and up +27.63% over the past month. Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
Previous Close:
$1.84
Open:
$1.94
24h Volume:
1,791
Relative Volume:
0.06
Market Cap:
$5.42M
Revenue:
-
Net Income/Loss:
-$14.11M
P/E Ratio:
-
EPS:
-$10.72
Net Cash Flow:
-$13.60M
1W Performance:
+2.65%
1M Performance:
+27.63%
6M Performance:
-29.45%
1Y Performance:
-75.44%
1-Day Range:
$1.94$1.94
1-Week Range:
$1.78$1.95
52-Week Range:
$1.04$9.00
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals IncSector
HealthcareIndustry
BiotechnologyPhone
443-776-3133Address
601 21ST STREET, SUITE 300, VERO BEACH, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS